Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention concerns derivatives of heteroarylsulfonamides, their preparation and their applications in human therapy, as blockers of Kv potassium channels and specifically channels Kv1.5, Kv4.3 and Kv11.1.
• Potassium channels represent the largest family of ion channels in the human genome, with approximately 80 genes (Tamargo et al., Cardiovasc. Res. 2004, 62: 9- 33) . These potassium channels can be subdivided into 3 sub-families: channels activated by potential or voltage (K v channels) and calcium (K Ca channels), inward rectifier channels (K ir ) and two-pore potassium channels (K 2p ).
• K v channels channels activated by potential or voltage
• K Ca channels calcium channels
• K ir inward rectifier channels
• K 2p two-pore potassium channels
• the sub-family of voltage-activated channels is the one most represented in the human organism, with an almost ubiquitous distribution in excitable cells (cardiac cells, neurons, striated or smooth muscle cells) and non-excitable cells such as pancreatic, prostatic, parathyroid cells, etc. (for review, Gutman G et al., Pharmacol. Rev. 2005, 57:473-508).
• the main function of the Kv potassium channels in excitable cells is the control of the resting membrane potential and of the action potential duration (Nerbonne and Kass, Physiol. Rev. 2005, 85:1205-1253). As such, several Kv channels are involved in this control, in both the heart auricles and ventricles.
• the Kv4.3 channels associated with the KChIP 2 sub-units form the current l t0 which is involved in the premature repolarisation phase of the action potential (PA) , the KVLQT1 /MinK and hERG channels which are involved in the late repolarisation phase of the PA (generating respectively currents l Ks and l Kr ).
• the abovementioned channels are distributed uniformly between the heart auricles and ventricles.
• FA atrial fibrillation
• anomalies form part of a phenomenon of myocardial remodelling, following a pressure overload or a stretching causing morphological alterations (hypertrophy, dilatation, fibrosis), as well as modifications in the regulation of the trans-membranous ionic currents, modifying the electrophysiological characteristics of the atrial myocytes.
• si nce atrial stasis is also related to the increase of intracavitary pressures (systolic or diastolic left ventricular dysfunction, valvular heart disease or valve replacement).
• Kv indicates the family of voltage-dependent potassium channels, and includes various sub-families (Kv1. , Kv2. , Kv3. etc.) among which are the Kv1.1 , Kv1.2, Kv1.3 channels, ... "A blocker of the Kv channels” denotes a molecule which reduces or blocks the K + ion flow through the channel.
• salts designates acid or base addition salts, notably mineral ones, of the compounds of the present invention, and notably base addition salts using bases such as LiOH, KOH or NaOH or acid addition salts using acids such as HCI.
• the salts are preferably pharmaceutically acceptable, i.e. they are non-toxic for the patient to whom they are administered.
• pharmaceutically acceptable refers to molecular entities and compositions producing no adverse or allergic effect, or other undesirable reaction when administered to an animal or a human.
• the term "pharmaceutically acceptable excipient” includes all diluents, additives or excipients, such as preservative agents, fillers, disintegrating agents, wetting agents, emulsifiers, dispersants, anti-bacterials or antifungals, or also agents allowing intestinal and digestive absorption and resorption to be slowed.
• preservative agents such as preservative agents, fillers, disintegrating agents, wetting agents, emulsifiers, dispersants, anti-bacterials or antifungals, or also agents allowing intestinal and digestive absorption and resorption to be slowed.
• preservative agents such as preservative agents, fillers, disintegrating agents, wetting agents, emulsifiers, dispersants, anti-bacterials or antifungals, or also agents allowing intestinal and digestive absorption and resorption to be slowed.
• disintegrating agents such as preservative agents, fillers, disintegrating agents, wetting agents, emulsifiers, dispersants, anti-bacterials or
• the purpose of the present invention is derivatives of heteroarylsulfonamides which are blockers of the Kv potassium channels (more specifically the Kv1 .5, Kv4.3 and Kv1 1 .1 channels) and their application in clinical therapy.
• R1 represents one or more substituents of the phenyl core X chosen from among the group consisting of: hydrogen , halogen (such as F , CI , Br) , trifl uoromethyl , trifluoromethoxy, linear or branched C C 4 alkyl, and linear or branched C C 4 alkoxy, n represents 0, 1 or 2,
• A represents oxygen or sulphur
• R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy
• HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C C 4 alkyl, a linear or branched C C 4 alkoxy , a halogen (such as F, CI, Br), or trifluoromethyl,
• the sulfonamide group (-NH-S0 2 HetAr) can be located on the phenyl core Y i ortho, meta or para of the position occupied by group D.
• Linear or branched C C 4 alkyl means, in the sense of the present invention, a linear or branched hydrocarbon chain, including 1 to 4 carbon atoms, such as the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl groups.
• Linear or branched C C 4 alkoxy means, in the sense of the present invention, a linear or branched C C 4 alkyl group as defined above linked to the remainder of the molecule th rough an oxygen atom , such as the methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy and tert-butoxy groups.
• the compounds of general formula I are those matching the following formula (la):
• R1 , R2, A, B, D, n and HetAr are as defined above,
• compounds of general formula I or la are those for which:
• R1 represents one or more substituents of the phenyl core X chosen from among the group consisting of: hydrogen, halogen (such as F, CI , Br) , trifluoromethyl, trifluoromethoxy, linear or branched C C 4 alkyl, and methoxy,
• n 1 ,
• A represents oxygen or sulphur
• R2 represents a hydrogen
• HetAr represents a 2-pyridyl or 8-quinolyl group, possibly substituted by a group such as methyl or trifluoromethyl,
• compounds of general formula I or la are those for which:
• R1 represents one or more substituents of the phenyl group X chosen from among the group consisting of: hydrogen, halogen (such as F, CI , Br) , trifluoromethyl, trifluoromethoxy, linear or branched C C 4 alkyl, and methoxy,
• A represents sulphur
• n 1 ,
• R2 represents a hydrogen
• HetAr represents a 2-pyridyl group, possibly substituted by a group such as methyl or trifluoromethyl,
• the purpose of the invention also concerns the pharmaceutically acceptable salts of the compounds of general formula I.
• the present invention also concerns the compounds of general formula I as well as their pharmaceutically acceptable salts for their use as a medicine.
• the present invention also concerns the compounds of general formula I as well as their pharmaceutically acceptable salts for their use as blockers of Kv potassium channels, and more particularly of the Kv1.5, Kv4.3 or Kv1 1.1 channels.
• the invention also concerns the compounds of general formula I as well as their pharmaceutically acceptable salts for their use as medicine intended for the treatment and/or prevention of illnesses requiring blockers of Kv potassium channels, and more particularly channels Kv1.5, Kv4.3 and Kv11.1.
• the invention also concerns the compounds of general formula I as well as their pharmaceutically acceptable salts for their use as medicine intended for the treatment and/or prevention of atrial fibrillation, heart rhythm disorders of the auricles and/or the ventricles, and pathologies in which the cell cycle and/or cell proliferation and/or regeneration are impaired (cancer, chronic inflammation).
• Pair is understood to mean a deterioration from an initial state.
• compositions characterised in that they contain as their active principle a compound of general formula I or one of its pharmaceutically acceptable salts.
• the invention also concerns a pharmaceutical composition characterised in that it contains a compound of general formula I or one of its pharmaceutically acceptable salts in association with at least one pharmaceutically acceptable excipient.
• compositions according to the invention can be administered orally, sublingually, subcutaneously, intramuscularly, intravenously, transdermal ⁇ , locally or rectally.
• the active ingredient may be administered in the form of administration units, blended with traditional pharmaceutical supports, to animals or to human beings.
• the appropriate administration unit forms include orally administered forms such as pills, capsules, powders, granules and oral solutions or suspensions, sublingual and by-mouth forms of administration, the subcutaneous, topical, intramuscular, intravenous, intranasal or intraocular forms of administration, and the rectal forms of administration.
• the formulations appropriate for the chosen form of administration are known by the skilled man in the art and described, for example, in: Remington, The science and Practice of Pharmacy, 19 th edition, 1995, Mack Publishing Company.
• the dosages of the compounds of formula I in the compositions of the invention can be adjusted to obtain a quantity of active substance which is effective in obtaining the desired therapeutic response for a composition particular to the method of administration.
• the effective dose of a compound of the invention varies according to numerous parameters such as, for example, the chosen method of administration, weight, age, sex, the nature of the pathology and the sensitivity of the individual requiring treatment. Accordingly, the optimum posology must be determined in accordance with parameters judged relevant, by the specialist in the field.
• the present invention also extends to the methods of chemical preparation of the compounds of general formula I as notably defined below.
• the compounds of the present invention can be synthesised by using the methods of synthesis described below, or by using methods of synthesis known to the skilled man in the art.
• the compound of formula I obtained in the previous step (a2) may be salified in the presence of a pharmaceutically acceptable base or acid in order to give a pharmaceutically acceptable salt of the compound of formula I.
• the compound of formula I obtained in the previous step (b3) may be converted into a salt in the presence of a pharmaceutically acceptable base or acid in order to give a pharmaceutically acceptable salt of the compound of formula I.
• the compound of formula I obtained in the previous step (c5) may be salified in the presence of a pharmaceutically acceptable base or acid in order to give a pharmaceutically acceptable salt of the compound of formula I.
• the intermediate and final compounds may if desired be purified using one or more methods of purification chosen from among extraction, filtration, chromatography on silica gel, preparatory HPLC in the normal or reverse phase, or crystallisation.
• 2-amino-5-fluoro-phenol (10 g, 79 mmol) is placed in the presence of potassium O- ethylcarbonodithioate (27.7 g, 173 mmol) in 100 mL of ethanol at reflux overnight. After reduction to dryness the residue is triturated in a solution of HCI 1 N, filtered and then rinsed with HCI 1 N. After drying under vacuum, 13.8 g of a brown solid is isolated (quantitative yield).
• Intermediate 1 b (solid) is prepared from 2-amino-4-tert-butyl-phenol using the procedure described for intermediate 1 a (yield 94%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -MeOH:90-10, Rf 0.83.
• Intermediate 1 b (solid) is prepared from 2-amino-4-chloro-phenol using the procedure described for intermediate 1f (yield: 46%).
• TLC silica gel 60 F 254 Merck, Petroleum ether- AcOEt:50-50, Rf 0.70.
• Intermediate 2g (oil) is prepared from intermediate 1 b using the procedure described for intermediate 2e (yield: 42%).
• TLC silica gel 60 F 254 Merck, Petroleum ether- AcOEt:50-50, Rf 0.76.
• Intermediate 3b (oil) is prepared from 6-chloro-2-benzoxazole-2-thiol using the procedure described for intermediate 3a (yield: 92%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -MeOH:90-10, Rf 0.11.
• Intermediate 3c (solid) is prepared from intermediate 1c using the procedure described for intermediate 3a (yield: 79%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -MeOH:90-10, Rf 0.15.
• Intermediate 3d (solid) is prepared from intermediate 1 d using the procedure described for intermediate 3a (yield: 91 %).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -MeOH:95-5, Rf 0.20.
• Intermediate 3j (oil) is prepared from intermediate 2b and [1 ,4]diazepane using the procedure described for intermediate 3e (yield: 83%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -MeOH:95-5, Rf 0. 10.
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -AcOEt:90-10, Rf 0.26.
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -MeOH:95-5, Rf 0.20.
• Compound 1 is prepared using synthesis method 1 : intermediate 3a (2.5 g, 1 1.30 mmol) is placed in the presence of 1 H-benzo[d][1 ,3]oxazine-2,4-dione (1.83 g, 1 1.3 mmol) and of DMAP (138 mg, 1.13 mmol) in 25 ml_ of THF and 5 ml_ of DMF and the mixture is stirred overnight at ambient temperature. After reduction to dryness the residue is taken up in water and extracted using AcOEt. After the organic phases are dried and after reduction to dryness the residue obtai ned is purified by flash chromatography on silica (CH 2 CI 2 -MeOH, gradient 100-0 to 95-5 over 40 min).
• Compound 2 is prepared using synthesis method 1 using intermediate 3e for the first step (yield: 87%) and intermediate 4b for the second step (yield: 30%).
• Compound 3 is prepared using synthesis method 1 using intermediate 3f for the first step (quantitative yield) and intermediate 4b for the second step (yield: 80%).
• Compound 4 is prepared using synthesis method 1 using intermediate 3g for the first step (yield: 72%) and intermediate 4b for the second step (yield: 27%) and then salified in the form of hydrochloride.
• Compound 5 is prepared using synthesis method 1 using intermediate 3h for the first step (yield: 87%) and intermediate 4b for the second step (yield: 23%).
• Compound 6 is prepared using synthesis method 1 using intermediate 3c for the first step (quantitative yield) and intermediate 4b for the second step (yield: 24%).
• Compound 7 is prepared using synthesis method 1 using intermediate 3d for the first step (yield: 74%) and intermediate 4b for the second step (yield: 31 %).
• Compound 8 is prepared using synthesis method 1 using intermediate 3g for the first step (yield: 94%) and intermediate 4a for the second step (yield: 56%).
• Compound 9 is prepared using synthesis method 1 using intermediate 3f for the first step (quantitative yield) and intermediate 4c for the second step (yield: 40%).
• the dihydrochloride is obtained by salt formation using a 5N solution of HCI in isopropanol (3 equivalents).
• Compound 12 is prepared using synthesis method 2 using intermediates 3g and 5b (yield: 15%).
• Compound 13 is prepared using synthesis method 2 using intermediates 3a and 5c (yield: 53%).
• Compound 14 is prepared using synthesis method 2 using intermediates 3b and 5c (yield: 56%).
• Compound 15 is prepared using synthesis method 2 using intermediates 3g and 5c (yield: 80%).
• Example 16 N-(2-(4-(6-bromobenzo[d]thiazol-2-yl)piperazine-1-carbonyl)phenyl)- quinoline-8-sulfonamide (16)
• Compound 16 is prepared using synthesis method 1 using intermediate 3f for the first step (yield: 97%) and quinoline-8-sulfonyl chloride for the second step (yield: 61 %).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 - MeOH: 95-5, Rf 0.73.
• Compound 17 is prepared using synthesis method 1 using intermediate 3b for the first step (yield: 73%) and quinoline-8-sulfonyl chloride for the second step (yield: 50%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 - MeOH: 95-5, Rf 0.68.
• Compound 18 is prepared using synthesis method 1 using intermediate 3g for the first step (yield: 94%) and quinoline-8-sulfonyl chloride for the second step (yield: 82%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 - MeOH: 95-5, Rf 0.61.
• Compound 19 is prepared using synthesis method 1 using intermediate 3i for the first step (yield: 91 %) and quinoline-8-sulfonyl chloride for the second step (yield: 67%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 - MeOH: 95-5, Rf 0.76.
• Compound 20 is prepared using synthesis method 1 using intermediate 3j for the first step (quantitative yield) and quinoline-8-sulfonyl chloride for the second step (yield: 58%).
• Compound 21 is prepared using synthesis method 3: intermediate 2e (0.21 g, 1.25 mmol) and intermediate 6a are placed in 5 mL of EtOH in the presence of 0.3 g (3.58 mmol) of sodium bicarbonate, and the mixture is then stirred for 2h at 80°C. After evaporation under reduced pressure the residue is taken up by water and extracted using AcOEt. After drying of the organic phases and reduction to dryness the residue obtained is triturated in a mixture of EtOH/Et 2 0 and 0.32 g of solid is isolated by filtration (yield: 77%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -AcOEt: 70-30, Rf 0.43.
• Compound 22 is prepared using synthesis method 3 using intermediates 2f and 6a (yield: 83%).
• Compound 23 is prepared using synthesis method 3 using intermediates 2g and 6a (yield: 82%).
• Compound 24 is prepared using synthesis method 3 using intermediates 2h and 6a (yield: 92%).
• TLC silica gel 60 F 254 Merck, CH 2 CI 2 -AcOEt: 70-30, Rf 0.33.
• Compound 25 is prepared using synthesis method 3 using intermediate 6a and 2- chloro-1,3-benzothiazole (yield: 81%).
• Compound 26 is prepared using synthesis method 3 using intermediate 6a and 2,6- dichloro-1,3-benzothiazole (yield: 82%).
• Compound 27 is prepared using synthesis method 3 using intermediates 2d and 6a (yield: 14%).
• Compound 29 is prepared using synthesis method 3 using intermediates 2a and 6b (yield: 76%).
• Compound 30 is prepared using synthesis method 3 using intermediate 6b and 2,6- dichloro-1,3-benzothiazole (yield: 80%).
• Compound 31 is prepared using synthesis method 3 using intermediates 2b and 6b (yield: 28%).
• Compound 32 is prepared using synthesis method 3 using intermediates 2c and 6b (yield: 51%).
• Example 33 lithium N-(2-(4-(6-bromobenzo[d]thiazol-2-yl)piperazine-1- carbonyl)phenyl)-p ridine-2-sulfonamide (33)
• Example 34 sodium N-(2-(4-(6-bromobenzo[d]thiazol-2-yl)piperazine-1- carbonyl)phenyl)-p ridine-2-sulfonamide (34)
• Compound 34 is prepared using synthesis method described in example 33 using a 1 M solution of NaOH. After filtration, compound 34 (2.46g) is isolated in the form of a solid and then dried under vacuum.
• Example 35 potassium N-(2-(4-(6-bromobenzo[d]thiazol-2-yl)piperazine-1- carbonyl)phenyl)-p ridine-2-sulfonamide (35)
• Compound 35 is prepared using synthesis method described in example 33 using a 1 M solution of KOH. After filtration, compound 35 (2.51 g) is isolated in the form of a solid and then dried under vacuum.
• the pharmacological evaluation of the compounds on potassium channel Kv1.5 was undertaken using a 96-well plate and FLIPR technology by thallium ion measurement.
• the HEK293 cells, transfected in a stable manner with the human isoform of the Kv1.5 channels, are seeded 24h before the experiment in 96-well plates (15 10 s cells/plate, 200 ⁇ /well) with polylysine applied in the following culture medium: DMEM, 10% SVF, Penicillin/Streptomycin, G418 as the selection antibiotic.
• the FLIPR experiment is undertaken using "FLIPR Potassium Ion Channel Assay Kit", as indicated by the manufacturer (Molecular Devices).
• the culture medium is replaced by the solution containing the thallium marker for 90min at 37°C.
• the compounds for testing are added to a final concentration of 10 ⁇ in the well for 15 min at 37°C.
• the basic fluorescence is then read for 60 sec.
• the addition of depolarising medium (20 mM of potassium and 3 mM of final thallium) opens the potassium channels and causes an increase of the fluorescence of the thallium fluorophore corresponding to an influx of thallium ions through the hKvl .5 channels.
• the measurement is made 30 sec after the injection of the depolarising solution.
• 10 ⁇ DPO Tocris, blocker of the Kv1 .5 channels
• BMS394136 is a blocker of the Kv1.5 channel under development at Bristol-Myers Squibb (Abstract, D. Xing et al., Circulation 2009, 120 (18S3): 2515).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=44246390

Family Applications (1)

Country Status (19)

Cited By (5)

Families Citing this family (9)

Citations (5)

Family Cites Families (6)

• 2010
  • 2010-11-23 FR FR1059634A patent/FR2967674B1/fr active Active
• 2011
  • 2011-11-03 TW TW100140099A patent/TWI576106B/zh not_active IP Right Cessation
  • 2011-11-17 AR ARP110104287A patent/AR083903A1/es unknown
  • 2011-11-23 US US13/822,406 patent/US8846930B2/en not_active Expired - Fee Related
  • 2011-11-23 NZ NZ610700A patent/NZ610700A/en not_active IP Right Cessation
  • 2011-11-23 JP JP2013540331A patent/JP5837085B2/ja not_active Expired - Fee Related
  • 2011-11-23 WO PCT/EP2011/070736 patent/WO2012069503A1/en not_active Ceased
  • 2011-11-23 AU AU2011333772A patent/AU2011333772B2/en not_active Ceased
  • 2011-11-23 CA CA2817531A patent/CA2817531A1/en not_active Abandoned
  • 2011-11-23 MY MYPI2013001836A patent/MY168283A/en unknown
  • 2011-11-23 MX MX2013005734A patent/MX352396B/es active IP Right Grant
  • 2011-11-23 EP EP11785690.6A patent/EP2643318A1/en not_active Withdrawn
  • 2011-11-23 KR KR1020137015172A patent/KR101838326B1/ko not_active Expired - Fee Related
  • 2011-11-23 BR BR112013012615A patent/BR112013012615A2/pt not_active IP Right Cessation
  • 2011-11-23 RU RU2013126251/04A patent/RU2582995C2/ru not_active IP Right Cessation
  • 2011-11-23 CN CN201180055123.XA patent/CN103209980B/zh not_active Expired - Fee Related
  • 2011-11-23 UA UAA201307746A patent/UA109295C2/uk unknown
• 2013
  • 2013-05-13 MA MA35892A patent/MA34658B1/fr unknown
  • 2013-05-21 IL IL226495A patent/IL226495A/en active IP Right Grant
• 2014
  • 2014-08-15 US US14/460,951 patent/US9156834B2/en not_active Expired - Fee Related

Patent Citations (5)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events